Oscient reiterated at market outperform

Oscient Pharmaceuticals Corp. was reiterated by JMP Securities analyst Adam Cutler at market outperform. According to NDC Health data, 118,400 Factive scripts were written in the first quarter of 2006, generating an estimated $8.4 million to $8.9 million in revenues, better than JMP's estimate of $8.3 million. For the week ended April 14, NDC reported that total Factive prescriptions were 5,011 (4,821 new), or 0.78% of weekly prescriptions for the quinolone class of antibiotics, compared with the previous week with 5,825 total prescriptions (5,585 new), or 0.87% of weekly prescriptions. Shares of the Waltham, Mass., biopharmaceutical company were down $2.02, or 1.13%, at $1.75 on volume of 166,611, shares versus the three-month running average of 497,652 shares. (Nasdaq: VRTX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.